# **Supportive Place for Observation and Treatment (SPOT)**



## Jessie M. Gaeta, MD

Chief Medical Officer, Boston Health Care for the Homeless Program Assistant Professor, Boston University School of Medicine



November 2018

# BHCHP's Main Practice









Chris (far left) shot heroin behind a house in Boston as his friend Shaun watched; they had just spent the night in a homeless shelter.

Sherry (above), a homeless woman who said she has been on and off drugs, leaned against a street sign outside the Cumberland Farms store at the corner of Mass. Ave. and Albany Street.

At left, Leonardo, wearing a Batman mask, walked along Mass. Ave. "I want to be able to work here," he said. "I'm not asking for a free check... I'm asking for a job and a place to live and to be part of

# LIFE AND LOSS ON METHADONE M

#### METHADONE MILE

EXETTABOOME AND I many clinics and services here try to steel themselves against the streets outlide. On the mornings when alse must brave the domain of the street of the street of the street of the street outlide. On the mornings when alse must brave the domain of the street of the street of the street of the domain of the street of the collect heads-top permitted for hack and gives them to vome alway no nucle alway on the road to recovery. Now, the lives in the street of the street ing for a retail service company. The sing-song offers of pills and dope make her stomach

That read's he said, "leads to nothing." But these streets were paved with suffering long before to-day's drug epidemic earned much notice. And in the wake of the closing of the Long Island Shelter, the chronically home-less mingle with a new generation caught in addiction's grip, parading this most confounding of problems out before an andhence at houg Boston intersection.

Even as a rising death toll stokes compassion and new-found resolve, gaping holes remain in the systems set up to combat the crisis – nowhere more visible than here. As more and more people stumble along the sidewalks of Methadone Mile each morning, those holes seem harder than ever to

ecovery and relapse jockey for space in the same few blocks. A constellation of services

<text><text><text><text>

not the country where you find . . . the level of services that your finding iters.". But the challenge of the area are obvious. Beeplite a heavy back the service of the s

with nowhere else to be — linger outside, crouching on the dusty roadiance. Methadome. Methadome. Horon, is one of the most different withdrawal symp-heroin, is one of the most effective treatments against opioid addiction, along with suboxone, a similar drug that can be taken at home. That's why this area's derive nickname infu-

<text><text><text><text><text><text>

haun stands shivering in front of the Cumber-land Farms store on Mass. Ave. and does the math: A week, maybe more, before he can get on suboxone after being kicked out of his metha-done clinic. Two hours before he 'll be dopesick. Less than §20 needed to buy a quarter-gram of heroin.

ampton Street every morning so she can get her methadone without succumbing to the temptation of the dealers she

without succentribing to the temptation of the dealers she passes on the wet. He is too add to go through withdrawal, he says. He doesn't wet wet, Then, subscore, the first he herein, just for sweek. Then, subscore, Shann, who goes by the nickname "hont?" (pronounced is the subscore of the subscore rest opoid crisis. For him, heroin serves as a refuge from a field most of the subscore of the subscore of the subscore rest opoid crisis. For him, heroin serves as a refuge from the subscore of the subscore of the subscore of the subscore rest opoid crisis. For him, heroin serves as a refuge from the subscore of the subscore of the subscore of the subscore occurrent a tunnihous schildhood, hospitalization for men-tal health issues, and repeated arrests. He started drinking and the docinements obscore and by 31 he was snoking and that



A police officer and a security guard chased an alleged drug dealer after he ran away during questioning; at right, police handcuffed the suspect as the guard stood by

snorting cocaine, and using LSD; he started using Oxycontin in the late '90s, he said, before switching to heroin. He served time for a failed robbery at a McDonald's. His brother died of

<text><text><text><text><text><text>



body. In many ways, the center of this teeming neighbor in many ways, the center of this teeming neighbor houd — the hub of the Mile — is not a shelter or a term of the cumbertand Farms on the corner of Massar The Cumbertand Farms on the corner of Massar ny's first forsy into an "urban location" in floaton mice 1981, and a month-long than during the floaton






His stomach is cramping. He is nauseated, and he is anx-ious: Soon, the diarrhea and vomiting will start, and pain so His stomach is cramping. He is nausested, and he is any situs: Soon, the diarches and yourniting will start and pain a solution of the start and the start and pain a solution of the start and start and the start and pain a method of the start and the start and the start and for several months, he says, and so has his wire for homan. Among his prison tatistos, he has her name inked across his before: Will quick this together how yours, they shall, hey have before: Will quick this together how yours, they shall, hey have before the start and the start and the strengt, and low one of the start and the strengt of the start low of the start reaching for the the walks her down South walks up at start gring in a homeless shelter, and

### OBJECTIVE

Implement a harm reduction program within a health care setting, in order to:

- 1. Prevent fatal overdose
- 2. More effectively connect highest-risk individuals with treatment
- 3. Tackle stigma





#### **PROGRAM CONCEPT**




#### **Services Offered**

- Medical monitoring during sedation
- Treatment of overdose (oxygen, IV fluids, naloxone)
- Counseling about safer injection techniques
- Connection to primary care, behavioral health services, and addictions treatment
- Naloxone rescue kit distribution

#### **Staffing Model**

- Registered nurse
   specializing in addiction
- Harm reduction specialist builds relationships and links people to treatment
- Rapid response clinician (MD/NP/PA) available for emergency







#### **CONSUMER INVOLVEMENT**

- Participated in weekly planning meetings
- Perspectives sought in survey conducted at syringe exchange program before opening
- Interviewed harm reduction applicants
- Patient experience survey




SUPPORTIVE PLACE FOR OBSERVATION AND TREATMENT





#### NEED SPOT OPERATIONS <u>RESULTS</u> CURRENT RESEARCH FUTURE RESEARCH CONCLUSION






1. León, C., Cardoso, L., Mackin, S., Bock, B., & Gaeta, J. M. (2017). The willingness of people who inject drugs in Boston to use a supervised injection facility. Substance Abuse, 1-7.

2. Cardoso, L. J., León, C., Bock, B., & Gaeta, J. Changes in community attitudes about substance use and harm reduction approaches after the opening of a new medical monitoring facility (in development).

3. León, C., Cardoso, L. J., Johnston, S., Mackin, S., Bock, B., & Gaeta, J. M. (2018). Changes in public order after the opening of an overdose monitoring facility for people who inject drugs. International Journal of Drug Policy, 53, 90-95.






#### WHAT WE'RE LEARNING

- Cohort using program is extremely high risk
- Nature of relationship with participants is quite different than in other clinical settings
- Substance use is layered with "cocktail"
  - Opioid
  - Benzodiazepine
  - Clonidine
  - Gabapentin
  - Promethazine
- Participants reluctant to seek health care services elsewhere because of stigma











Vital signs monitoring in SPOT often shows bradycardia and hypotension, in addition to sedation and respiratory depression, thought to be a result of polysubstance use.





	Cluster A: Mild (N=81 episodes)	Cluster B: Moderate (N=136 episodes)	Cluster C: Severe (N=88 episodes)
Sedation level (0-6), mean (SD)	3.6 (0.8)	4.5 (0.6)	4.5 (0.5)
Sedation level ≥5, N (%)	2 (2.5)	70 (51.5)	41 (46.6)
Systolic blood pressure nadir (mm Hg), mean (SD)	113.5 (13.3)	94.5 (13.6)	89.2 (12.8)
Systolic blood pressure nadir <90mm Hg, N (%)	4 (4.9)	54 (39.7)	43 (48.9)
Pulse nadir (beats/min), mean (SD)	80.2 (18.0)	57.3 (11.1)	59.2 (11.9)
Pulse nadir <60 beats/min, N (%)	10 (12.4)	83 (61.0)	53 (60.2)
Respiratory rate nadir (breaths/min), mean (SD)	13.5 (1.9)	11.7 (0.9)	11.7 (0.8)
Respiratory rate <12 breaths/min, N (%)	3 (3.7)	18 (13.2)	14 (15.9)
Oxygen saturation nadir (%), mean (SD)	95.8 (2.2)	95.4 (1.5)	91.1 (1.7)
Oxygen saturation <95%, N (%)	21 (25.9)	41 (30.2)	88 (100)

#### FITable 1. Characteristics of intoxication clusters

#### Qualitative description of clusters:

Cluster A: mild sedation with stable vital signs

Cluster B: moderate sedation with non-hypoxic vital sign abnormalities

Cluster C: moderate sedation with hypoxia and other vital sign abnormalities



Table 2. Demographic and self-reported substance ingestion characteristics overall and by intoxication cluster
--

	Overall	Cluster A: Mild	Cluster B: Moderate	P value	Cluster C: Severe	P value
	(N=305 episodes)	(N=81 episodes)	(N=136 episodes)	(B vs A)	(N=88 episodes)	(C vs A)
Demographics						
Age (years), mean (SD)	39.0 (9.4)	38.0 (10.0)	37.5 (8.8)	0.77	42.3 (9.0)	0.04
Female, N (%)	137 (44.9)	29 (35.8)	59 (43.4)	0.38	49 (55.7)	0.07
Substance ingestions						
Opioids, N (%)	219 (71.8)	66 (81.5)	96 (70.6)	0.10	57 (64.8)	0.02
Sedating medications, N (%)						
Benzodiazepines	172 (56.4)	29 (35.8)	83 (61.0)	0.001	60 (68.2)	< 0.001
Clonidine	165 (54.1)	24 (29.6)	86 (63.2)	< 0.001	55 (62.5)	0.002
Promethazine	114 (37.4)	16 (19.8)	64 (47.1)	< 0.001	34 (38.6)	0.03
Gabapentin	112 (36.7)	16 (19.8)	61 (44.9)	< 0.001	35 (39.8)	0.03
Any of above	193 (63.3)	34 (42.0)	92 (67.7)	0.001	67 (76.1)	< 0.001
Stimulants, N (%)						
Cocaine/crack	18 (5.9)	8 (9.9)	6 (4.4)	0.15	4 (4.6)	0.20
Methamphetamine	5 (1.6)	2 (2.5)	2 (1.5)	0.60	1 (1.1)	0.52
Any of above	23 (7.5)	10 (12.4)	8 (5.9)	0.11	5 (5.7)	0.14
Cannabinoids, N (%)						
Marijuana	3 (1.0)	1 (1.2)	2 (1.5)	0.89	0 (0)	
Synthetic cannabinoids	17 (5.6)	6 (7.4)	10 (7.4)	0.99	1 (1.1)	0.10
Any of above	20 (6.6)	7 (8.6)	12 (8.8)	0.97	1 (1.1)	0.07
Alcohol, N (%)	11 (3.6)	5 (6.2)	3 (2.2)	0.23	3 (3.4)	0.41

**Qualitative summary:** Cluster B and C patients were more likely to have ingested sedating medications. Cluster C patients were slightly older, marginally more likely to be female, less likely to have ingested opioids, and marginally less likely to have ingested cannabinoids.



Table 3. Multivariable associations with intoxication cluster membership.

	Adjusted OR (95% CI) Cluster B vs A	Adjusted OR (95% CI) Cluster C vs A
Demographics		
Age, per 10 years	0.93 (0.64, 1.36)	1.54 (1.00, 2.35)
Female	1.44 (0.71, 2.92)	2.51 (1.03, 6.10)
Substance ingestions		
Opioids	0.65 (0.27, 1.61)	0.53 (0.23, 1.25)
Sedating medications	2.75 (1.40, 5.40)	3.38 (1.48, 7.70)
Stimulants	0.57 (0.22, 1.47)	0.64 (0.20, 2.02)
Cannabinoids	1.29 (0.41, 4.01)	0.24 (0.03, 2.10)
Alcohol	0.28 (0.06, 1.44)	0.37 (0.09, 1.54)

**Qualitative summary:** In multivariable models, ingestion of sedating medications was the strongest predictor of intoxication syndrome severity. Older age and female sex were associated with higher odds of severe (cluster C) intoxication syndromes.



#### **SPOT RESEARCH CHALLENGES**

- Not insignificant issues around gaining consent
  - Desire to maintain trusting relationships with participants
  - Participants' engagement in illicit behavior
  - Sedation and its impact on ability to give consent
- Need to prevent research from being viewed as encouraging participants to use again
- At SPOT, beginning data collection at unknown time point in symptom progression
- Difficult to follow participants over time given the instability in their lives





1. Environment	2. Participant Population	3. Impact
<ul> <li>✓ 1A. Consumer</li> <li>willingness to use harm</li> <li>reduction program</li> </ul>	<ul><li>✓ 2A. Internal dashboard</li><li>/ population profile</li></ul>	3A. Impact of SPOT on OD rates & ED utilization
<ul> <li>✓ 1B. Community perceptions of SPOT</li> </ul>	2B. Polysubstance overdose syndrome (case series)	3B. Impact of SPOT on SUD treatment initiation & engagement
<ul> <li>✓ 1C. Evaluating public order, pre- and post-SPOT (first 12 weeks)</li> </ul>	2C. Participant substance use patterns, acute & chronic health issues	3C. Changes in SPOT user risk behavior over time (cohort study)



- Disproportionate effect of overdose deaths among homeless population
- Harm reduction services play a crucial and complementary role in SUD treatment continuum
- SPOT doesn't go far enough unable to prevent fatal OD at point of injection



# What do we see?

Image courtesy Boston Globe

www.bhchp.org @BHCHP

0



# With Thanks

SPOT Clinical Team Led by Kate Orlin & Courtney Kenney

## **BHCHP Leadership**

Barry Bock, CEO James O'Connell, President

### **AHOPE**

of Boston Public Health Commission

# BHCHP's Institute for Research, Quality, and Policy in Homeless Health Care

Travis Baggett, Director of Research Casey K. León, former Institute Director Gabriel Wishik, MD Melanie Racine, Project Manager Lena Cardoso, Research Associate Salem Johnston, Analyst

# Contact:

Jessie M. Gaeta, MD Chief Medical Officer, Boston Health Care for the Homeless Program 780 Albany St. Boston, MA 02118 Assistant Professor, Boston University School of Medicine

jgaeta@bhchp.org

